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Legends to figures 
Figure 1: Costs for the infected total hip arthroplasty (THA) and matched  
    noninfected THA 1. 
Figure 2: Estimated historical (2001-2011) and projected total inpatients  
cost of infections with total hip arthroplasty (THA), total knee arthroplasty (TKA)       
and combined THA and TKA procedures within the United States between 2001 
and 2020 2. 




















DTT   Difficult-to-treat 
DNase  Deoxyribonuclease 
EBJIS   European Bone and Joint infection Society 
IDSA   Infectious Diseases Society of America 
MiRNA  MicroRNA 
MSIS   Musculoskeletal Infection Society 
PJI   Periprosthetic joint infection 
THA   Total hip arthroplasty 
















1.1.  Significance of periprosthetic joint infection as revision cause  
Arthroplasty of the hip and knee joint is a successful elective surgical procedure with more 
than 95% survivorship at 10-year follow-up in patients with advanced osteoarthritis 4, 5. In 
the last decades there was a major increase of the number of implanted arthroplasties in 
Germany and about around 300.000 hip and knee arthroplasties were performed in the 
year of 2014 6. Similar to the trend in Germany in the UK and USA more than 800.000 
arthroplasty surgeries are done annually 7, with expectations that more than 4 million 
arthroplasty surgeries will be performed by the year 2030 4. Concomitantly, the number 
of revision surgeries is expected to be on rise. Periprosthetic joint infection (PJI) is 
estimated to occur in 1-2% in primary and in 4% in revision arthroplasties 3, 4, 8-10 and was 
in Germany the second frequent reason for revision surgery in patients with primary hip 
arthroplasty after aseptic loosening in year 2015 3. Revision procedures continue to 
impose substantial economic and social burdens, studies showing higher costs, longer 
hospitalization and higher number of readmissions in patients with revision surgery due 






Figure 1: Costs for the infected total hip arthroplasty (THA) and matched noninfected THA 
1. Reprinted with permission from Elsevier. 
 
Infection costs in the USA alone was expected to be more than 900 million US dollars in 
2012 with projections to be greater than 1.6 billion US dollars by 2020 2, 12 (Figure 2). 
Moreover, PJI has a major effect on functional outcome and mortality of the patients, as 
the relative mortality risk of a patient, who undergoes a revision due to PJI is 2.18 times 
higher compared to a patient, who do not require any revision surgery after primary 
arthroplasty 13. One-year mortality could even be 3.1 times higher in patients with 




Figure 2. Estimated historical (2001-2011) and projected total inpatients cost of infections 
with total hip arthroplasty (THA), total knee arthroplasty (TKA) and combined THA and 
TKA procedures within the United States between 2001 and 2020. Solid lines represent 
the historical trends; dashed lines are projected values for each procedure. For both 
historical and projected values, the dotted lines represent the 95% confidence intervals 2. 
Reprinted with permission from Wolters Kluwer Health, Inc. 
 
1.2.  Pathogenesis of PJI 
Classification of PJI depends on the type of pathogenesis and the time of symptom 
manifestation after prosthesis implantation 14. Pathogenetically, seeding of the 
microorganisms can be either exogenously or hematogenously 15. Around two thirds of 
 
9 
PJI occur typically exogenously due to intraoperative inoculation of the implants or in the 
early postoperative phase in case of wound healing complications 9. Hematogenous 
infections are caused by a seeding from a distant primary focus via blood stream at any 
time after surgery 16. Therefore, all implants remain susceptible to hematogenous 
infection during their whole indwelling time, as high vascularity of periprosthetic tissue 
and presence of a foreign body weakens the host defense 3.  
Timely manifestation of PJI depends mostly on the virulence of the causative 
microorganism. Early infections (< 2 months after surgery) are associated with clear 
clinical signs of infection, such as redness, swelling, fever and frequently caused by high-
virulent microorganisms such as Staphylococcus aureus or streptococci, while patients 
with delayed infections (between 2 months and 2 years after surgery) present often with 
a stealth-type of infection, having mostly chronic pain as the only symptom 9. The latter is 
typically caused by low-virulent microorganisms, such as coagulase-negative 
staphylococci or Cutibacterium acnes 17. Late infections (> 2 years after surgery) are 
typically caused by hematogenous seeding of high-virulent microorganisms, leading 
therefore mostly to acute onset of symptoms. Skin and soft-tissue infections and 
cardiovascular infections are the most common origins of hematogenous spread 16. Other 
less frequent origins include urinary, respiratory or gastrointestinal tract, as well as oral 
cavity 18. Although the identification of primary infectious focus in hematogenous PJI is 
crucial to prevent recurrences, the primary focus can be found out only in 68% of the 





1.3. Role of biofilm 
Microorganisms persist preferentially in biofilms, rather than in free-floating planktonic 
form in most environments, including human body 19, 20. Within biofilms, microorganisms 
are surrounded of a polymeric matrix and create well-organized complex communities, 
mimicking multicellular organisms 9, 21. An estimated 80% of human infections and most 
of the PJIs are attributed to biofilms, where the microorganisms escape from host defense 
and are up to 1000 times more resistant to antimicrobial agents than their planktonic 
counterparts 3, 22, 23. Moreover, the surfaces of commonly implanted foreign bodies such 
as titanium, stainless steel, cobalt-chromium and polymethylmethacrylate are highly 
susceptible to infection and reduce the minimal infecting dose of microorganisms more 
than 100,000-fold 24-26. Therefore, antimicrobial activity requires penetration into the 
biofilm matrix to eradicate infection. High biofilm activity could have been demonstrated 
in recent studies only for few antibiotics, including rifampicin against staphylococcus 
infections and ciprofloxacin against Gram-negative infections 27-30. Better cure rates were 
achieved in patients with PJI, if biofilm-active treatment was used, compared to 
conventional regimes 31-35. Therefore, it is believed that microorganisms, for which no 
biofilm-active antimicrobial therapy exists, associate with worse treatment outcomes and 
are referred as difficult-to-treat (DTT) 14, 36. Given that most of the current antibiotics tend 
to suppress rather than eradicate biofilms, there is an urgent need for biofilm treatment in 






1.4. Management of periprosthetic joint infection 
The main purpose of PJI treatment is to achieve a pain-free and functional prosthetic joint, 
which can be best achieved by a combination of antimicrobial and surgical therapy. The 
initial antimicrobial therapy is mostly empiric and often applied intravenously to lower the 
bacterial load prior oral treatment 14. After identification of the causative microorganisms 
a targeted therapy should be applied according to the recommendation of the infectious 
disease specialists depending on the antibiotic susceptibility. A therapy with rifampin or 
fluoroquinolones should start only after reimplantation (in case of an exchange 
arthroplasty), when all drains are removed and the wound is dry, not to emerge any 
antibiotic resistance 37. Currently there are no controlled studies testing the ideal length 
of the antimicrobial treatment, however a total antimicrobial treatment of 12 weeks is 
mostly recommended in literature 3, 38. Surgical techniques include debridement with 
retention of the prosthesis, one- or two-stage exchange, resection arthroplasty, 
arthrodesis and amputation depending on the infection duration and severity 9. Figure 3 
summarizes most important treatment options and antimicrobial treatment strategy. 
Debridement and implant retention can be performed successfully in acute infections 
when: (1) prosthesis is stable; (2) duration of symptoms is short; (3) soft tissues are intact; 
and (4) difficult-to-treat microorganisms are absent 15, 39. In cases with longer duration of 
symptoms with maturation of the biofilm a complete removal of the arthroplasty is 
mandatory. One-stage exchange is gaining popularity as data continue to show similar 
outcomes compared to a two-stage exchange 40, 41. The most important profit of this 
procedure is that explantation and reimplantation is performed in a single surgery and 
hospitalization. Despite indications and contraindications for one-stage exchange are 
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changing with time, overall strict exclusion criteria include culture-negative infections, 
severely compromised bone and soft tissues, antibiotic-resistant microorganisms, 
enterococcal infections, and history of a prior surgery due to infection 41-44.   
 
 
Figure 3. Overview of surgical procedures and antimicrobial therapy strategy 3 
 
Although the best treatment option of PJI is unclear, two-stage exchange arthroplasty, 
including removal of the components and insertion of an antibiotic-impregnated cement 
spacer in the first stage and reimplantation of the prosthesis at a later stage, still remains 
the gold standard for the treatment of chronic PJI in most countries 45. The first stage 
consists of removal of all the implants, as well as all infected and necrotic tissue, bone 
cement and all other foreign material, which can maintain infection. An antimicrobial-
impregnated spacer can then be placed to keep the limb at its correct length. Recently, a 
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study showed significantly greater range of motion and higher Knee Society scores, as 
well as shorter hospital stays in patients with articulating spacers compared to patients 
with static spacers for the treatment of knee PJI 46. The second stage is mostly used as 
another opportunity to perform a substantial debridement before the reimplantation of the 
definitive prosthesis.  
 
1.5. Outcomes after two-stage exchange arthroplasty 
The management of PJI continues to be challenging and incurs higher complication rates 
and poorer patient outcomes compared with primary total joint arthroplasty 47. A 
reinfection after a failed PJI treatment could ultimately result in further high economic 
costs and worsen patient outcomes. Factors affecting the successful eradication of PJI 
include host comorbidities, soft tissue conditions, virulence of the affecting 
microorganism, antimicrobial treatment and the surgical technique 47-50. The reported 
outcomes in literature after two-stage exchange varies, with some studies showing a 
100% rate for infection eradication 47, 51-58. However, the results remain unpredictable, as 
current data regarding PJI may lead to unfounded, inaccurate conclusions and some 
rates of failure of > 20% continue to be reported 50, 54, 59, 60. Moreover, the absolute number 
of patients with treatment failure can be more than reported. The majority of those studies 
focused on the clinical outcome following reimplantation does not accurately reflect the 
overall success rate of two-stage exchange, since patients, who do not undergo 
reimplantation after the first stage are not included in the calculations. Recent studies 
were able to show, that 1 in 5 patients undergoing the first stage do not undergo 
subsequent reimplantation for a variety of reasons, such as infection persistence or 
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mortality 51, 55, 61. Independent significant risk factors for mortality are host grade and 
severe comorbidities, which are also associated with failure after two-stage exchange 
arthroplasty 51, 61.  Furthermore, patients with persistent infection after the first stage, who 
undergo a spacer exchange demonstrate poorer outcomes, including failure to undergo 
reimplantation and twice the failure rate 45. Current two-stage exchange protocols remain 
imperfect to address PJI. With the knowledge of PJI pathogenesis and risk factors for 
failure, optimization of current treatment strategies is needed to improve outcome of 


















1.6. Scientific question  
There is a great need to identify the factors leading to failure to ultimately achieve a 
successful two-stage exchange and to optimize infection-free survival. The purpose of 
this habilitation script was scientific evaluation of factors predictive of failure in a two-
stage arthroplasty in patients with knee and hip PJI and to find answers to the following 
questions. 
- Can PJI patients infected with microorganisms, for which no biofilm-active 
treatment exists, be treated as successfully as PJI patients with more susceptible 
microorganisms with a two-stage exchange arthroplasty? 
- What is the association between positive cultures at the time of reimplantation and 
subsequent failure in two-stage exchange arthroplasty? 
- What is the role of patient independent risk factors, such as selection of surgery 
strategy, type of antimicrobial treatment and missed infection foci, in the failure of 
two-stage exchange arthroplasty? 
- Can a multidisciplinary team approach provide better outcomes in the treatment of 
patients with PJI? 
- Are all reinfections after a presumed successful two-stage exchange arthroplasty 
persistent infections and should be treated with a new two-stage exchange
  
2. Results  
2.1.  Streptococcal periprosthetic joint infection  
  
High failure rates in treatment of streptococcal periprosthetic joint infection  
Akgün D, Trampuz A, Perka C, Renz N. Bone 




Invasive streptococcal infections in adults are in increase in last two decades, involving 
also periprosthetic joint infections, so about 10% of PJIs are caused by these  
microorganisms and the frequency is expected to rise 62, 63. Although streptococcal 
infections were thought to be easy to treat due to their broad antimicrobial sensitivity, 
recent literature has shown conflicting data about the outcomes of treatment for  
streptococcal PJI 62, 64-66. Furthermore, it is unknown, whether rifampicin, which plays a 
key role in eradication of staphylococcal biofilms, is also effective against biofilm built by 
streptococci 14. The purpose of this study therefore was to evaluate the pathogenesis, 
clinical characteristics and outcomes of treatment in patients with streptococcal PJI.  
Furthermore, the influence of rifampin on the treatment outcome was also analyzed 49.   







30 Patients with a streptococcal PJI (12 hip and 18 knee arthroplasties) treated between 
January 2009 and December 2015 were included in the study. The Kaplan-Meier survival 
analysis was performed to assess the probability of infection-free survival. 
 
Results 
The infection was hematogenous in 16 and perioperative in 14 patients. The infection-
free survival at three years with 12 patients at risk was only 59% (95% confidence interval 
39-75%) 49. Furthermore, treatment failure was observed in 45% of the patients, who were 
managed with a two-stage exchange arthroplasty. Treatment with or without rifampin 
included in the antibiotic regime did not change the treatment outcome (p=0.175) 
 
Discussion 
This study showed a very low success rate in patients with streptococcal PJI in contrast 
to former belief, that streptococcal infections are easy to treat due to wide spectrum of 
antimicrobial sensitivity. The common route of infection is hematogenous and the most 
failures occur in the first year after treatment, so treating physicians should prompt a 
search for the potential primary source of infection, follow-up their patients closely and 
consider long-term antimicrobial suppression in order to optimize the treatment outcome 
67. The results of this study raise the question, whether streptococci should be classified 
as difficult-to-treat microorganism, which are associate with worse treatment outcome due 




2.2. High rate of infect eradication in patients with difficult-to-treat 
microorganisms 
 
Outcome of hip and knee periprosthetic joint infections caused by pathogens resistant to 
biofilm-active antibiotics: results from a prospective cohort study 
Akgün D, Trampuz A, Perka C, Renz N. 




Implant-associated infection is caused by surface-adhering microorganisms persisting as 
biofilm, which is resistant to host defense and antimicrobial agents 14. This topic is gaining 
more importance in the era of rising antimicrobial resistance and only few antimicrobial 
agents are available, which possess anti-biofilm activity such as rifampin against 
staphylococcal biofilms and ciprofloxacin against Gram-negative biofilms 27, 28, 68-70. 
Recent literature showed higher rates of infection eradication in patients with 
staphylococcus PJI, who were treated with rifampin combinations compared to patients 
without biofilm-active agents 34, 35. Therefore, it is believed that microorganisms, for which 
no biofilm-active antimicrobial therapy exists, associate with worse treatment outcomes 
and are referred as DTT 14, 36. In patients with a DTT PJI a two-stage exchange with a 
long interval (>6 weeks) is recommended, however it is not known whether the absence 




non-DTT PJI if a two-stage exchange is used 68. The aim of this study was therefore to 
compare the outcome of patients with DTT and non-DTT PJI. 
 
Methods 
Patients with hip and knee PJI, who were treated in our institution between 2013 and 
2015 were prospectively included in this study and Kaplan-Meier survival analysis was 




The treatment success rate was similar in patients with a DTT PJI compared to patients 
with a non-DTT PJI (80% vs 84%, p=0.61). Hospital stay, prosthesis-free interval and 
duration of antimicrobial treatment were significantly longer in patients with DTT PJI. 
 
Discussion 
Patients with a DTT PJI can be treated as successfully as patients with a non-DTT PJI, if 
longer prosthesis-free interval and longer antimicrobial treatment are carried out. 
However, some studies reported that some pathogens can be dormant for a long time in 
the absence of an implant and re-emerge at the time of reimplantation, which can lead to 




2.3. Higher failure rate in patients with positive microbiology at the time of 
reimplantation  
 
A positive bacterial culture during re-implantation is associated with a poor outcome in 
two-stage exchange arthroplasty for deep infection  
Akgün D, Müller M, Perka C, Winkler T. 




The decision, whether to reimplant a new prosthesis or perform another spacer exchange  
at the time of the second stage in two-stage exchange arthroplasty is mainly based on 
intraoperative macroscopic appearance and combination of serological tests as well as 
aspiration analysis 72. However, there are no well recognized tests or clinical analyses by 
which to determine the best time for the second stage 50. Furthermore, the association 
between a positive culture at the time of the second stage and subsequent failure is 
unclear and only one study was able to find that a positive culture carries an increased 
risk of failure 59. The purpose of this study was to analyze the relationship between a 









A total of 163 patients with a hip or knee PJI between 2013 and 2015 were retrospectively 
included. Logistic regression analysis was performed to determine the predictors of risk 
factors for failure after two-stage exchange arthroplasty. 
 
Results 
The same initially infecting microorganism was isolated at the reimplantation in 33.3% of 
patients. The risk of failure of treatment was significantly higher in patients with a positive 
culture at the time of reimplantation (odds ratio=1.7, p=0.049) and in patients with a higher 
Charlson Comorbidity Index (odds ratio=1.5, p=0.001) 50. 
 
Discussion 
A positive culture at reimplantation and higher comorbidity were independently associated 
with two-times the risk of subsequent failure. Prolonged antimicrobial treatment after the 
reimplantation in patients with positive cultures should be implemented to enhance the 
infection eradication rate after two-stage exchange arthroplasty. Furthermore, medical 




2.4. High rate of patient independent failure cause in treatment of periprosthetic joint 
infection   
  
Failure analysis of infection persistence after septic revision surgery: a checklist algorithm for 
risk factors in knee and hip arthroplasty  
Kilgus S, Karczewski D, Passkönig C, Winkler T, Akgün D, Perka C, Müller M.  
Arch Orthop Trauma Surg. 2020 Apr 15. 
  https://doi.org/10.1007/s00402-020-03444-0 
   
  
Introduction  
Common risk factors affecting the successful eradication of PJI include host comorbidities, 
soft tissue conditions and virulence of the affecting microorganism 47-50. However, in most 
cases the failure cannot be explained by these factors alone and treating physician dependent 
errors in surgical and antimicrobial treatment can play an essential role. This study aimed to 
identify those possible and specific reasons such as the selection of surgical strategy, type of 




The following text is adopted from the above mentioned publication 73.  In a prospective 
analysis all patients were included that were treated: (1) at our institution, (2) with a twostage 






previous revision for PJI. A checklist algorithm, which is based on international guidelines,  
was used to identify possible reasons for infection 73. 
 
Results 
In most of the patients (85%) included in this study at least one patient independent 
failure reason could have been identified. The leading error was inadequate therapy 
concept in 50% of the patients followed by inadequate surgical debridement (33%), 
inadequate antimicrobial therapy (30%) and missed external bacterial primary focus 
(13%). After the individual failure analysis, all 70 patients were treated with a two-stage 
exchange in our department and in 94.9% infection freedom could be achieved 
(34.3 ± 10.9 months follow-up) 73. 
 
Discussion 
In most of cases with treatment failure after septic treatment at least one possible treating 
physician dependent error can be found, of which inadequate antimicrobial treatment and 
inadequate debridement are the most important issues. Further diagnostic or therapeutic 
errors include the use of serum inflammatory biomarkers to rule out PJI, incomplete 
evaluation of joint aspirate and overreliance on suboptimal diagnostic criteria 74. In 
patients with a treatment failure the entire previous management should be assessed for 
errors. A high rate of infection-free survival after two-stage exchange arthroplasty may be 





2.5. The importance of multidisciplinary team approach in the treatment of 
periprosthetic joint infection 
 
High cure rate of periprosthetic hip joint infection with multidisciplinary team approach 
using standardized two-stage exchange 
Akgün D, Müller M, Perka C, Winkler T. 




Multidisciplinary team approach plays an essential role in decision-making and have 
become the standard of care for malignant neoplasms in many countries. Especially in 
more complex cases it guarantees to define the best possible treatment plan specific for 
the patient 75, 76. Recent literature also confirmed that multidisciplinary team approach 
may affect clinical outcome and patient survival 77, 78. Similar to the treatment of patients 
with malignancy, management of patients with PJI involves multiple medical steps, which 
necessitates close interdisciplinary work-up of orthopedic surgeons, infectious disease 
specialist and microbiologist. The purpose of this study was to report the outcome of our 
two-stage revision protocol, in which a multidisciplinary team guides the management of 
all patients, and all diagnostic and treatment processes are based on a standardized 







The following text is adopted from the above mentioned publication 79. All hip PJI episodes 
treated between march 2013 and may 2015 were prospectively included. The infection-
free survival was assessed by using the Kaplan-Meier survival method. Furthermore, 
patients were dichotomized into two groups depending on the number of previous septic 
revisions, duration of prothesis-free interval, positive culture with difficult-to-treat 
microorganisms, microbiology at explantation and microbiology at reimplantation 79.  
 
Results 
A total of 84 patients could have been included in the study. The Kaplan-Meier estimated 
infection-free survival after 3 years was 89.3% with 30 patients at risk. Coagulase-
negative staphylococci were the most common isolated pathogens followed by 
Staphylococcus aureus and Cutibacterium. There were no statistical differences in 
infection-free survival among the dichotomized groups. 
 
Discussion 
Management of prosthetic joint infections is a very challenging task with many possible 
sources of errors in the diagnosis and treatment. Thus, it obligates a multidisciplinary 
team approach in the management of the patients with PJI to achieve the highest infect 
eradication rates. Furthermore, it can lead to a decrease in the usage of antibiotics, a 
reduction in surgeries performed as well as shortened hospital stay, which not only 
reduces treatment side effects but also improves economic feasibility 75. The members of 




to recognize failures in an early stage and to induce the right treatment choice in case of 






2.6. Hematogenous infection as an often-unrecognized cause of recurrent 
infection after two-stage exchange arthroplasty 
 
An often-unrecognized entity as cause of recurrent infection after successfully treated 
two-stage exchange arthroplasty: hematogenous infection  
Akgün D, Müller M, Perka C, Winkler T. 
Arch Orthop Trauma Surg. 2018 
Sep;138(9):1199-1206. https://doi.org/10.1007/s00402-018-2972-3.  Epub 2018 Jun 5. 
 
Introduction 
Reinfection after two-stage exchange arthroplasty is a challenging clinical scenario with 
limited data on adequate treatment guidelines 39. It can be due to of either failure to 
eradicate the previous infection or an infection with a new pathogen 39, 80, 81. However, the 
data existing in literature dealing with the latter group is scarce. Beside the possibility of 
an infection with a new microorganism at the time of reimplantation, a hematogenous 
spread from another infection focus can play a crucial role. The distinction between both 
routes is the key in deciding the appropriate treatment option, as patients with an acute 
infection can be treated successfully with a debridement and implant retention and two-
stage exchange in these patients will be an overtreatment with possible worsening of 
clinical outcomes 15. The aim of this study was to establish the incidence and 
characteristics of reinfection due to a hematogenous seeding after a successful two-stage 
exchange arthroplasty and to raise awareness about this entity to reduce the number of 





All consecutive treated patients between 2013 and 2015 with a two-stage exchange 
arthroplasty due to hip and knee PJI (93 hips and 89 knees) were included. Patients were 
followed up prospectively to identify recurrent infections to identify recurrent infections 
due to hematogenous spread. 
 
Results 
 After a mean follow-up of 31.8 months 6% of the patients had a hematogenous 
reinfection. In all but two cases were the microorganism causing the new infection other 
than isolated at the time of the initial two-stage exchange. The primary focus could have 
been identified only in 46% of patients.  
 
Discussion 
Hematogenous infection after a successful two-stage exchange arthroplasty is a rare but 
very important cause of a reinfection. In these cases, debridement and implant retention 
can be performed with success. Furthermore, it is essential to identify the primary 





3.1. Controversy of treatment success in two-stage exchange arthroplasty 
Two-stage exchange arthroplasty is furthermore the gold standard for the treatment of 
chronic PJI in most countries and is practiced almost more than 20 years 45. However, 
there is still a very widespread heterogeneity on the reporting success rates in literature. 
This is based on several facts. First, most of the published studies are designed 
retrospectively and include patients from a wide range of time interval. Since the 
diagnosis and especially antimicrobial and surgical therapy of PJI is evolving 
unexpectedly fast, patients included in these retrospective studies lack mostly a 
standardized surgical and most importantly antimicrobial treatment algorithms leading to 
inhomogeneous study cohorts. This can conduce to higher failure rates among the 
patients with inadequate therapy and thereby alter the overall success rate of the 
mentioned surgical procedure 55, 59, 82.  
Second, there is a lack of an internationally accepted definition of PJI. The most known 
definitions include Musculoskeletal Infection Society criteria (MSIS) 83, Infectious 
Diseases Society of America (IDSA) criteria 84 and European Bone and Joint infection 
Society (EBJIS) criteria 85. Each definition criteria use different cut off values for diagnostic 
tests and include or exclude different diagnostic tools in their definition. Although definitive 
evidence or major criteria for infection are identical between different definitions, the 
supportive evidence or minor criteria differ and are less agreed upon, which makes the 
diagnosis difficult especially in patients with low-grade infections 83. A recent article 
showed that whereas MSIS and IDSA criteria may miss some patients with PJI (false 




aseptic as having PJI (false positive), leading to unnecessary surgical interventions and 
antimicrobial treatment 86. This variety causes non-comparable study cohorts with 
different success rates depending on the applied definition. 
Third, treatment success after two-stage exchange arthroplasty varies dramatically 
depending on the criteria used to define success 87. Although considerable efforts have 
been made to standardize the definition of PJI treatment success using the Delphi 
international consensus criteria 88, several problems are frequently encountered. Many 
patients do not complete the second stage of a two-stage exchange arthroplasty and are 
not considered in success definitions 45. The common reasons for not being able to 
complete the intended reimplantation are patient-related comorbidities and mortality, 
polymicrobial PJI and patient choice 51. Every effort should be made to provide the 
opportunity for reimplantation in every single patient 51. A further problem is that the 
microorganism causing the reinfection is mostly different than of the initial causative 
microorganism 39, 50. Although this may be considered as success from a microbiological 
standpoint, the patient still needs to undergo revision surgery due to PJI. Furthermore, 
attributing mortality to PJI is often subjective and difficult.  
Thus, the success rate after two-stage exchange arthroplasty varies significantly between 
published studies making the results difficult to compare due to limitations mentioned 
above. 
 
3.1.  Impact of causative microorganism on the treatment success  
Infecting microorganisms adhere rapidly to foreign material forming biofilms, where they 




the context of implant-associated infections but also in many other infections is well 
studied 14. Studies analyzing the biofilm resistance have shown that minimal inhibitory 
concentration of several antibiotics is significantly increased if microbes form biofilms 22. 
Thus, antibiotics need to penetrate into the biofilm matrix in order to eradicate infection. 
Several studies demonstrated high biofilm activity of rifampicin against staphylococcus 
infections and ciprofloxacin against Gram-negative infections 27-30. Therefore, pathogens, 
for which no biofilm active antimicrobial treatment exists, are referred as DTT and include 
rifampin-resistant staphylococci, fluoroquinolone-resistant Gram-negative bacteria, 
enterococci and fungi 68. These microorganisms were associated with higher infect 
eradication failure rates compared to other more susceptible microorganisms 36, 89, 90. 
However recent data shows similar eradication rates in patients with DTT PJI compared 
to non-DTT PJI, if patients are treated with a two-stage exchange with a long interval (>6 
weeks) and receive longer antimicrobial treatment 68, 91. Based on these findings the term 
DTT PJI may not be appropriate, since in patients undergoing a two-stage exchange 
arthroplasty with a long interval no biofilm-active antibiotics are required to achieve good 
results 92. 
Another uncertainty of treatment success exists in streptococcal PJI. It was believed that 
streptococcal infections are readily amenable to treatment due to high sensitivity to 
antibiotics. Some studies reported high success rates in streptococcal PJI, even if the 
prosthesis was retained 64-66. However other studies showed failure rates as high as 40% 
in patients with streptococcal PJI 49, 62, 67, 93. The wide range may reflect various definitions 
of success used by different studies. Akgün et al. have shown a high failure rate in infect 




isolation of streptococcus species as an independent risk factor of failure after one-stage 
exchange arthroplasty 94. The results of the study by Renz et al. also supported these 
findings 67. They showed however, that the administration of long-term suppressive oral 
antimicrobial treatment was associated with significantly better outcome in streptococcal 
PJI and suggested to consider it irrespective of surgical treatment.  
Thus, the individualization of antimicrobial and surgical therapy regimes enables similar 
success rates in patients irrespective of causative microorganism.   
 
3.2. The importance of multidisciplinary team approach in the management of 
PJI 
Patients suffering of PJI have mostly poorer health status with severe comorbidities as 
well as systemic and local compromised immune status due to scar tissue after multiple 
previous surgeries. This systemic and local immune failure can massively decrease the 
minimal infecting dose of bacteria and predispose to problems with infect eradication 50. 
Akgün et al. have shown a significantly higher risk of treatment failure in patients with a 
higher Charlson Comorbidity Index 50. Further studies emphasized the high rate of 
mortality in patients with high a Charlson Comorbidity Index and host grade after the first 
stage of two-stage exchange arthroplasty 55, 61. Thus, medical optimization of these 
patients is highly recommended both before and during the PJI treatment to enhance our 
treatment success. Also, Heller et al. recently published a checklist implementing a 
medical optimization to minimize the risk of postoperative infection, which also can be 
integrated in two-stage exchange arthroplasty 95. This is however only possible with a 




specialists and orthopedic surgeons, who should be involved in every stage of PJI 
treatment for each patient.  
The role of this multidisciplinary team gets even more important, since the management 
of patients with PJI does not include only surgical treatment but as importantly adequate 
antimicrobial treatment to achieve best treatment outcomes. Kilgus et al. recently reported 
on treating physician dependent causes leading to PJI treatment failure 73. They identified 
in 85% of patients with a PJI treatment failure at least one possible reason, which could 
have been prevented. An inadequate surgical therapy and inadequate antimicrobial 
treatment were the two most important identified reasons. After an individualized failure 
analysis, they achieved in their study cohort an infection-free survival of 94.9% with a two-
stage exchange arthroplasty. Thus, they recommended a critical review of the failed 
cases and a multidisciplinary approach by using a checklist algorithm throughout the 
entire PJI treatment. In another study, Ntalos et al. established a systematic 
multidisciplinary team approach in the treatment of PJI and assessed its effect on clinical 
decision-making 75. Their results showed that performing regular multidisciplinary case 
discussions led to a significant alteration in the treatment plan, including significant 
reduction of used antibiotics and number of surgeries performed. This improvement could 
be explained by a more pronounced consideration and reevaluation of diagnosis and 
treatment indications in a multidisciplinary team. Consequently, high infection eradication 
rates could have been achieved in a challenging cohort using a standardized two-stage 






3.3. New infection after successful two-stage exchange arthroplasty 
Reinfection after two-stage exchange arthroplasty is a very challenging clinical scenario 
with limited data on adequate treatment suggestions. Some previous studies showed that 
the pathogens isolated at the time of reinfection were different than the pathogens 
isolated at the time of initial treatment 50, 81, 96. The distinction of the route and duration of 
the new infection is however crucial in the decision-making of the most appropriate 
treatment. While a perioperative reinfection from the time of the reimplantation with a new 
microorganism and a longer duration of symptoms (>4 weeks) should be treated with a 
one- or two-stage exchange arthroplasty, an acute infection mostly due hematogenous 
seeding with short duration of symptoms (<4 weeks) can be managed with debridement 
and retention of the prosthesis, which is not as damaging as prosthesis exchange for 
patients 15, 39. Most importantly, a possible identification of a primary infection source in 
patients with a new hematogenous PJI should be performed in order to avoid recurrent 













4. Summary and outlook 
The aim of this habilitation script was to arm the treating physicians with an 
armamentarium of knowledge to achieve better success in eradicating PJI. Therefore, the 
published data concentrated on identification of the factors leading to failure in two-stage 
exchange arthroplasty in patients with PJI and on optimization of infection-free survival. 
Microbial biofilm makes the diagnosis and the treatment of PJI more challenging and 
therefore biofilm-active antibiotics are crucial to enhance treatment success.  
Microorganisms, for which no biofilm active antibiotic exits, presents a major difficulty in 
achieving high infect eradication rates in these patients. According to the results of this 
habilitation script however, an individualization of antimicrobial and surgical therapy 
regimes with a longer prothesis-free interval and longer antibiotic administration may 
enable achieving similar success rates in patients irrespective of causative 
microorganism after two-stage exchange arthroplasty.  
Furthermore, the data presented in this habilitation script emphasizes the implementation 
of a treatment supported by a multidisciplinary team approach as a crucial step to optimize 
outcome in patients with PJI. It could have been shown, that high infection eradication 
rates can be achieved by using a standardized two-stage exchange arthroplasty 
supported by a multidisciplinary team even in a challenging patient cohort. 
Given the fact, that there is a wide variety in the definition of PJI and its treatment success, 
which causes a heterogeneity of existing studies, further research is highly needed on 
more precisely defining PJI and success. Thus, consistency in definition between studies 
will enhance the overall quality of existing literature. Especially, when defining treatment 




as this prevent patients from unnecessary surgical interventions and antimicrobial 
treatment.  
Treatment of PJI in the near future will be more difficult with the increasing age and 
comorbidities of the patients in the era of rising antimicrobial resistance. Forthcoming 
studies providing a better understanding of the pathophysiology of PJI on the human body 
will allow us to correctly identify the infecting microorganisms and their virulence factors 
and develop newer treatment strategies. Success of our future treatment strategies will 
depend on improving the indications and technique of our current surgical procedures as 
well as the biofilm disrupting technologies 97. Recently it was shown, that enzyme 
deoxyribonuclease (DNase) can inhibit biofilm formation up to 60 hours and Kaplan et al. 
were able to show that DNase can increase the sensitivity of the biofilm to antibiotics in 
an in vivo model 97-99. Thus, it can be used as preventive biofilm agent in the management 
of PJI. Furthermore, the use of nanotechnology can help us in disrupting bacterial 
biofilms. In a study of Iannitelli et al. loaded nanoparticles with antimicrobial agents were 
able to decrease the stability of the biofilm matrix. As conclusion they stated that adding 
antibiotics into the nanoparticles can be use against bacterial biofilms 100. 
 
Finally, the field of genomics likely holds the key to a novel diagnostic and treatment 
approach to infection 97. With the help of genomics, we can better understand the 
pathophysiology of PJI, determine biomarkers of infection and so make an early 
identification with intervention possible. Recently, it has been shown with increasing 
evidence that micro-RNA (MiRNA) regulation plays an essential role in the immune 




tuberculosis or E. coli alter the expression of specific miRNA patterns in a host organism 
101-103. MiRNAs are small, non-coding molecules consisting about 18-24 nucleotides and 
have an important role in almost all biological processes. (e.g. stem cell differentiation, 
apoptosis, bone metabolism and aging processes) 103. In recent years, the determination 
of certain miRNA species as diagnostic and prognostic biomarkers in patients with 
bacterial infections and sepsis has been increasingly applied 101. At present, there are no 
published data that have investigated a correlation between certain systemically present 
miRNA expression patterns and PJI. It can be hypothesized, that the identification of a 
typical miRNA profile in patients with a PJI could improve the preoperative diagnosis and 
help treating physicians planning a better treatment strategy, especially in patients with 
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